The webcast will take place at 3:00 p.m. ET on Thursday, January 15, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/hc2026/ or directly at https:/ ...
Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today ...
Hamburg, 12.01.2025 – Aqua free, a leading European provider of drinking-water hygiene solutions, is launching Shower2go, a portable travel shower for consumers. Designed for hotels, holiday rentals, ...
BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on January ...
Matthews, NC, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Southern Pain and Spine Specialists is proud to announce that Dr. Ammar Alamarie, MD, has been recognized as a Castle Connolly Top Doctor for Pain ...
Exclusive U.S. Distribution Partnership with Enlight Medical Ltd. Enables Kaneka Medical America LLC to Bring Novel Neurovascular Guidewire Technology to the U.S. Market ...
At Praxis, Dr. Devinsky will be part of the group leading clinical strategy and global medical affairs, guiding program architecture, evidence generation, and external scientific engagement as the ...
DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), the world’s largest diversified manufacturer of professional dental products and technologies, and Benco Dental, the nation’s largest ...
Received record multi-system order in the fourth quarter from an existing Top 20 global biopharma customer to automate global manufacturing network. Full year 2025 total revenue expected to be ...
In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the ...
The Company remains fully committed to its core medical device activities, continuing to advance product development, preclinical and clinical studies, and regulatory progress – including products ...
Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia; PARIS, FRA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback